discovered before we landed on the moon.
It's Time.
Expanesthetics is being built by the anesthesia community. Our next private investment offering is now open.*
We're developing a new generation of inhaled anesthetics designed to maintain hemodynamic stability.
Here's why over 100 clinicians have already joined us.
The field is waking up to the risks of hypotension
A growing body of evidence suggests that intraoperative hypotension (IOH) may have a more significant impact on patient outcomes than previously recognized. Patient safety and regulatory agencies have begun to respond.
The APSF published consensus recommendations on perioperative hemodynamic instability[1] and issued a public safety announcement on the risks of intraoperative hypotension.[2]
Hypotension is the most common adverse event associated with surgeries and procedures according to a US government report,[3] and CMS has incorporated intraoperative hypotension into the MIPS reporting program as a marker of care quality.[4]
Three compounds that are normotensive at MAC
Our discovery platform has identified compounds that affect fewer unintended receptors and produce anesthesia while preserving hemodynamic stability in preclinical models[5], a profile no currently approved inhaled anesthetic can match.
Shaped by those who
practice it every day
Over 100 anesthesiologists and other anesthesia clinicians across the United States are building the future. Their continued backing reflects both confidence in the science and a belief that new anesthetic options can make a meaningful clinical and financial impact.
Will you help launch what's next?
Sign up to learn more about Expanesthetics and about our opportunity.*
Want to learn more first?